Unraveling α-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson's disease

Yuhang Zhou, Minchao Lai, Bowen Shu, Bo Wang, Dian Wang, Haoran Liu, Bo Li, Jianhe Guo, Dongjie Hu, Mingyuan Li, Cheng Zhu, Minseok Kang, Zhong Li, Renzhi Wang, Yong Zhao, Rocky S. Tuan, Keying Guo, Chenzhong Li, Jiang ChengTheranostics 2025 · DOI

TL;DR

This study confirms the existence of α-synuclein (α-syn) and amylin co-aggregates in Parkinson's disease (PD) patients, suggesting this co-aggregation is a key driver of PD pathology and a promising biomarker for early diagnosis. They developed a novel detection method for these co-aggregates in blood samples and EVs, showing their levels correlate with disease severity and diabetes markers.

What Problem Does This Paper Address?

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the aggregation of α-synuclein. A puzzling observation is the increased risk of PD in patients with diabetes, but the underlying mechanism has remained unclear. This paper investigates the hypothesis that the co-aggregation of α-synuclein with amylin, a peptide implicated in type 2 diabetes, plays a crucial role in this link and in PD pathogenesis. Current methods for detecting protein aggregates are often limited in their ability to specifically identify and quantify co-aggregates, hindering the investigation of their role in disease.

Methods

The researchers employed a multi-pronged approach:

  • In Silico Modeling: AlphaFold-3 was used to predict the structural feasibility of α-syn and amylin co-aggregation.
  • Molecular Dynamics (MD) Simulations: These simulations explored the hydrogen bonding interactions between α-syn and amylin fragments to understand their stable co-aggregation.
  • Surface Plasmon Resonance (SPR): This technique was used to quantify the binding affinity between α-syn and amylin.
  • Co-Immunoprecipitation (co-IP) and Western Blotting: These methods confirmed the presence of both α-syn and amylin in artificial co-aggregates and in cell lysates.
  • Transmission Electron Microscopy (TEM): TEM was used to visualize the morphology of α-syn, amylin, and co-aggregate fibrils, revealing distinct structural differences.
  • Novel Detection Method: A key contribution is the development of a surface-based fluorescence distribution method utilizing a dual-channel, "aggregate-only" detection system. This system uses a pair of antibodies to specifically identify co-localized α-syn and amylin signals, minimizing false positives from individual monomers. This method was applied to both serum samples and brain-derived extracellular vesicles (EVs) isolated using L1CAM as a marker.

Datasets

The study utilized clinical samples from:

  • Health Controls (HC)
  • Parkinson's Disease (PD) patients
  • Multiple System Atrophy (MSA) patients

Specific sample sizes are mentioned for different analyses (e.g., n=21 for serum analysis, n=20 for L1EV analysis in the PD vs. HC cohort; n=8 for the MSA/PD/HC cohort comparison).

Key Insights and Ideas

  • Amylin as a "Partner in Crime": The study provides strong evidence that amylin doesn't just coexist with α-syn in PD but actively participates in its aggregation, forming stable co-aggregates. This bridges the gap between diabetes and PD.
  • Co-aggregation as a Distinct Pathological Entity: The findings suggest that co-aggregation is not merely a consequence of individual protein aggregation but a unique pathological process with its own structural and functional implications.
  • EVs as Superior Biomarkers: Brain-derived EVs (L1EVs) proved to be more sensitive and specific for detecting co-aggregates compared to free-floating serum components, likely due to their direct origin from neural tissue.
  • Diagnostic Potential Beyond PD: The distinct distribution patterns of co-aggregates in serum versus EVs between PD and MSA patients suggest this approach could also aid in differentiating these neurodegenerative diseases.

Key Results

  • Confirmation of Co-aggregation: The study successfully confirmed the existence of α-syn-amylin co-aggregates in PD patient serum and L1EVs.
  • Diagnostic Power: The co-aggregate count in L1EVs showed a high diagnostic performance for distinguishing PD patients from healthy controls, with an AUC of 0.87, significantly outperforming α-syn aggregate detection in L1EVs (AUC = 0.67).
  • Correlation with Disease Progression: Co-aggregate counts in L1EVs showed a significant positive correlation with the UPDRS-III score (r = 0.582), indicating a link to PD severity.
  • Link to Diabetes: Serum co-aggregate count showed a weak positive correlation with HbA1c (r = 0.314), while L1EV co-aggregate count showed a stronger correlation (r = 0.561), reinforcing the diabetes-PD connection.
  • Differential Distribution in Synucleinopathies: While PD patients showed elevated co-aggregates in both serum and L1EVs, MSA patients only showed elevated levels in L1EVs, suggesting distinct pathogenic mechanisms.

Limitations and Future Work

  • Coincidental Positives: The authors acknowledge that their detection method, while innovative, might have a small chance of detecting spatially adjacent but not truly aggregated targets. The stability of the positive rate in patient samples was also noted as a limitation.
  • Binding Affinity Discrepancy: Their SPR results for binding affinity were less potent than those reported by other labs, which they attribute to using a more classical technology and potential steric hindrance.
  • Aggregate Size and Toxicity: The study did not deeply explore how co-aggregation affects aggregate size and its subsequent toxicity, which they suggest is a crucial area for future research.
  • Membrane Permeability: The membrane permeability of co-aggregates and their malignancy potential require further investigation.
  • Larger Cohort Studies: The findings regarding the differential distribution in MSA versus PD warrant confirmation in larger cohorts.
  • Mechanism of Amylin Transport: The precise mechanism of amylin transport into the brain and its role in co-aggregation needs further elucidation.
  • Kinetic Modeling: A detailed kinetic model of co-aggregation is recommended for future studies.

Summary updated

Abstract

<b>Background:</b> Patients with diabetes have a higher morbidity in Parkinson's disease (PD) than others, but the mechanism underlying this link remains controversial. The co-aggregation of α-synuclein (α-syn) and amylin has been hypothesized as a key contributor. <b>Methods:</b> Molecular interaction analysis and co-immunoprecipitation were conducted to assess the feasibility of co-aggregation. We developed a tailored surface-based fluorescence distribution method to detect the co-aggregate in the subject's serum sample and brain-derived L1CAM-positive Extracellular Vesicles. Subjects include Health Controls (HC), PD patients and multiple system atrophy (MSA) patients. <b>Results:</b> The co-aggregates were detected in PD patient samples, in both serum and brain-derived extracellular vesicles (EVs). We demonstrated that the co-aggregate count could distinguish PD patients from healthy individuals. Our results revealed a positive correlation between co-aggregate count and Parkinson's disease scales or diabetes markers, highlighting the role of co-aggregation in promoting PD progression. The distribution of co-aggregates demonstrated diversity among different α-synucleinopathies; a high co-aggregates count was found in EVs and serum of PD patients, but not in the serum of MSA patients. <b>Conclusion:</b> The existence of α-syn-amylin co-aggregates was confirmed. Our findings suggest that α-syn-amylin co-aggregation may play a pivotal role in PD pathology, and have the potential as a biomarker. These results point to a potential path for early-diagnosis and therapeutic intervention.
BibTeX
@inproceedings{zhou2025unraveling,
  author = {Yuhang Zhou and Minchao Lai and Bowen Shu and Bo Wang and Dian Wang and Haoran Liu and Bo Li and Jianhe Guo and Dongjie Hu and Mingyuan Li and Cheng Zhu and Minseok Kang and Zhong Li and Renzhi Wang and Yong Zhao and Rocky S. Tuan and Keying Guo and Chenzhong Li and Jiang Cheng},
  title = {{Unraveling α-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson's disease}},
  booktitle = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.112396},
}
Figure